Rumors are swirling that Pfizer is looking to take over the German biotech MediGene [1]. Shares of the smaller company leapt more than 12 percent today as reports of a possible deal hit the newswires. Neither company would comment on whether they've held talks, as reports suggest.
MediGene specializes in cancer, autoimmune disease [2] and skin disease; its two marketed products are the prostate cancer treatment Eligard and a genital warts med Veregen. European approval for a skin drug, Oracea, is pending. In the pipeline: a pancreatic cancer drug, Endotag.
- see the story [3] in Forbes
- check out the brief [4] at Thomson Merger News
Related Articles:
Woe is Pfizer, analysts say [5]
Pfizer suffers as big drugs falter [6]
Pfizer's Kindler can't quash mega-deal talk [7]
Analysts not impressed with Pfizer [8]
Links:
[1] http://www.fiercebioresearcher.com/story/medigene-advances-viral-approach-to-treating-cancer/2007-07-10
[2] http://www.fiercebiotech.com/story/also-noted-medigene-begins-trial-in-ra-study-finds-women-shortchanged-on-ch/2007-01-23
[3] http://www.forbes.com/afxnewslimited/feeds/afx/2008/05/14/afx5006597.html
[4] http://www.thomsonmergernews.com/story.asp?sectioncode=722&storycode=267183
[5] http://www.fiercepharma.com/story/woe-is-pfizer-analysts-say/2008-04-18
[6] http://www.fiercepharma.com/story/pfizer-roche-suffer-as-big-drugs-falter/2008-04-17
[7] http://www.fiercepharma.com/story/pfizer-s-kindler-can-t-quash-mega-deal-talk/2008-03-10
[8] http://www.fiercepharma.com/story/analysts-not-impressed-with-pfizer/2008-03-06